journal
MENU ▼
Read by QxMD icon Read
search

Therapeutic Advances in Chronic Disease

journal
https://www.readbyqxmd.com/read/28491268/umeclidinium-in-chronic-obstructive-pulmonary-disease-latest-evidence-and-place-in-therapy
#1
REVIEW
Kesavan Suresh Babu, Jaymin Bhagwanji Morjaria
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity, mortality and health care expenditure throughout the world. COPD guidelines recommend the use of long-acting muscarinic antagonist (LAMA) either alone or in combination with a long-acting β2 agonist (LABA). For over 10 years, tiotropium was the only LAMA that was used in the management of COPD. Over the past few years, various new drugs have been identified that act on the muscarinic receptors and β2 receptors. Umeclidinium (Umec) is a new LAMA currently approved for use in patients with COPD either as monotherapy or in combination with vilanterol (Vil)...
April 2017: Therapeutic Advances in Chronic Disease
https://www.readbyqxmd.com/read/28491267/update-on-the-management-of-giant-cell-arteritis
#2
REVIEW
Janet Roberts, Alison Clifford
Giant cell arteritis (GCA) is a large vessel vasculitis that may be associated with significant complications such as blindness, stroke, or aortic aneurysm and dissection in a subset of patients. Given the serious side effects associated with prolonged courses of glucocorticoids and frequent relapses experienced when doses are tapered, increased efforts are being dedicated to the discovery of safer and more effective therapies to control this disease. The purpose of this review is to critically evaluate the role of glucocorticoid-sparing agents in the medical management of GCA with a special focus on the most recent evidence regarding the role of biologic agents, including tocilizumab (TCZ), abatacept and ustekinumab, and other novel therapies...
April 2017: Therapeutic Advances in Chronic Disease
https://www.readbyqxmd.com/read/28348727/steps-forward-in-the-treatment-of-pulmonary-arterial-hypertension-latest-developments-and-clinical-opportunities
#3
REVIEW
Jessica B Badlam, Todd M Bull
Pulmonary arterial hypertension (PAH) is a chronic disease that results in narrowing of the small pre-capillary pulmonary arteries leading to elevation of pulmonary artery pressure and pulmonary vascular resistance, subsequent right ventricular failure, and if unchecked, death. Advances in the treatment of PAH over the last two decades have markedly improved survival. These improvements reflect a combination of changes in treatments, improved patient care strategies, and varying disease phenotypes in the PAH population...
February 2017: Therapeutic Advances in Chronic Disease
https://www.readbyqxmd.com/read/28348726/targeting-patients-with-asthma-for-omalizumab-therapy-choosing-the-right-patient-to-get-the-best-value-for-money
#4
REVIEW
Abir Al Said, Breda Cushen, Richard W Costello
The asthma syndrome has many manifestations, termed phenotypes, that arise by specific cellular and molecular mechanisms, termed endotypes. Understanding an individual's asthma phenotype helps clinicians make rational therapeutic decisions while the understanding of endotypes has led to the development of specific precision medications. Allergic asthma is an example of an asthma phenotype and omalizumab, a monoclonal antibody that neutralizes serum immunoglobulin (Ig)E, is a specific targeted treatment which was developed as a result of an understanding of the endotype of allergic asthma...
February 2017: Therapeutic Advances in Chronic Disease
https://www.readbyqxmd.com/read/28203348/flibanserin-for-hypoactive-sexual-desire-disorder-place-in-therapy
#5
REVIEW
Faina Gelman, Jessica Atrio
The pathophysiology, diagnosis and treatment of female sexual interest in pre- and post-menopausal women present a complex arena for patients and physicians to navigate. Flibanserin was the first pharmacologic treatment, approved by the United States Food and Drug Administration in August 2015, for hypoactive sexual desire disorder (HSDD) in premenopausal women. Side effects, contraindications and lack of approval in postmenopausal women are all limitations, as are issues surrounding patient and physician knowledge and access...
January 2017: Therapeutic Advances in Chronic Disease
https://www.readbyqxmd.com/read/28203347/killing-two-birds-with-one-stone-successful-opioid-monotherapy-in-intractable-migraine-triggered-epilepsy-a-case-series
#6
REVIEW
Iraj Derakhshan
The novel concept explored in this case series is the primacy of headaches in generating seizures in those patients who suffer from migraine-triggered epilepsy. In this series, once the migraine headaches were fully suppressed, via daily scheduled opioid therapy, the seizures also stopped. Seizures returned, however, after the patients stopped the opiate regimen for any reason. The above pharmacological scenario is reminiscent of a similar but naturalistic course of events reported on the salutary effects of ketogenic diet, or changes in life style, in similar cases of migraine-triggered epilepsy...
January 2017: Therapeutic Advances in Chronic Disease
https://www.readbyqxmd.com/read/28203346/ezetimibe-an-update-on-its-clinical-usefulness-in-specific-patient-groups
#7
REVIEW
Daniel Hammersley, Mark Signy
The aim of pharmacological lipid modification is to reduce low-density lipoprotein cholesterol (LDL-C) as a means of either secondary or primary prevention of cardiovascular disease. Statins are the first-line therapy for pharmacological lipid modification. Ezetimibe is a drug which reduces LDL-C by selectively inhibiting intestinal cholesterol absorption. This provides an alternative pharmacological approach to that of statin therapy to reduce LDL-C. Ezetimibe has been shown to significantly reduce levels of LDL-C and recently, as demonstrated in the IMPROVE-IT trial, to reduce the rate of cardiovascular events in high-risk patients...
January 2017: Therapeutic Advances in Chronic Disease
https://www.readbyqxmd.com/read/27803793/sacubitril-valsartan-in-heart-failure-latest-evidence-and-place-in-therapy
#8
REVIEW
Edgardo Kaplinsky
Despite significant therapeutic advances, patients with chronic heart failure (HF) remain at high risk for HF progression and death. Sacubitril/valsartan (previously known as LCZ696) is a first-in-class medicine that contains a neprilysin (NEP) inhibitor (sacubitril) and an angiotensin II (Ang-II) receptor blocker (valsartan). NEP is an endopeptidase that metabolizes different vasoactive peptides including natriuretic peptides, bradykinin and Ang-II. In consequence, its inhibition increases mainly the levels of both, natriuretic peptides (promoting diuresis, natriuresis and vasodilatation) and Ang-II whose effects are blocked by the angiotensin receptor blocker, valsartan (reducing vasoconstriction and aldosterone release)...
November 2016: Therapeutic Advances in Chronic Disease
https://www.readbyqxmd.com/read/27803792/mepolizumab-for-severe-refractory-eosinophilic-asthma-evidence-to-date-and-clinical-potential
#9
REVIEW
Francesco Menzella, Mirco Lusuardi, Carla Galeone, Sofia Taddei, Nicola Facciolongo, Luigi Zucchi
Severe asthma is characterized by major impairment of quality of life, poor symptom control and frequent exacerbations. Inflammatory, clinical and causative factors identify different phenotypes and endotypes of asthma. In the last few years, new treatment options have allowed for targeted treatments according to the different phenotypes of the disease. To accurately select a specific treatment for each asthmatic variant, the identification of appropriate biomarkers is required. Eosinophilic asthma is a distinct phenotype characterized by thickening of the basement membrane and corticosteroid responsiveness...
November 2016: Therapeutic Advances in Chronic Disease
https://www.readbyqxmd.com/read/27583124/the-relationship-of-management-modality-in-saudi-patients-with-type-2-diabetes-to-components-of-metabolic-syndrome-%C3%AE-glutamyl-transferase-and-highly-sensitive-c-reactive-protein
#10
Suhad M Bahijri, Maimoona Ahmed, Khalid Al-Shali, Samia Bokhari, Amani Alhozali, Anwar Borai, Amani Gusti, Ghada Ajabnoor, Ahmed Alghamdi, Mohammed Asiri, Jaakko Tuomilehto
BACKGROUND: The aim of this study was to investigate the relationship among management modality, glycemic control, components of metabolic syndrome (MS) and serum levels of γ glutamyl transferase (GGT) and C-reactive protein (CRP) in patients with type 2 diabetes (T2DM). METHODS: Patients with T2DM, not suffering from diabetes complications, were recruited from outpatients clinics at two hospitals in Jeddah. Anthropometric measurements and blood pressure (BP) were taken...
September 2016: Therapeutic Advances in Chronic Disease
https://www.readbyqxmd.com/read/27583123/antipsychotic-use-in-dementia-a-systematic-review-of-benefits-and-risks-from-meta-analyses
#11
Rajesh R Tampi, Deena J Tampi, Silpa Balachandran, Shilpa Srinivasan
BACKGROUND: The purpose of this review is to evaluate the data on the use of antipsychotics in individuals with dementia from meta-analyses. METHODS: We performed a literature search of PubMed, MEDLINE, EMBASE, PsycINFO and Cochrane collaboration databases through 30 November, 2015 using the following keywords: 'antipsychotics', 'dementia' and 'meta-analysis'. The search was not restricted by the age of the patients or the language of the study. However, in the final analysis we only included studies involving patients that were published in English language journals or had official English translations...
September 2016: Therapeutic Advances in Chronic Disease
https://www.readbyqxmd.com/read/27583122/prescribing-attitudes-behaviors-and-opinions-regarding-metformin-for-patients-with-diabetes-a-focus-group-study
#12
Katy E Trinkley, Daniel C Malone, Jennifer A Nelson, Joseph J Saseen
BACKGROUND: The purpose of this study was to identify the reasons why metformin prescribing is suboptimal. METHODS: Two semi-structured focus groups with attitudinal questionnaires and a brief educational presentation were held in two US cities. Participants included providers (physicians, pharmacists, midlevel practitioners) caring for patients with type 2 diabetes mellitus (T2DM) in an ambulatory setting. Outcome measures included provider attitudes, behaviors and opinions regarding the use of metformin...
September 2016: Therapeutic Advances in Chronic Disease
https://www.readbyqxmd.com/read/27433311/ustekinumab-in-crohn-s-disease-evidence-to-date-and-place-in-therapy
#13
REVIEW
Tal Engel, Uri Kopylov
Crohn's disease (CD) is an inflammatory bowel disease (IBD) with uncertain etiology. Biologic agents have revolutionized the treatment of CD but nonresponders remain a challenge. Ustekinumab is an interleukin 12/23p40 inhibitor that was recently found effective in treating CD. We reviewed the current literature regarding the efficacy of ustekinumab in treating CD and concluded that ustekinumab is a novel, promising and relatively safe agent for the treatment of moderate to severe CD. Additional data from randomized controlled studies and real-life cohorts are pending...
July 2016: Therapeutic Advances in Chronic Disease
https://www.readbyqxmd.com/read/27433310/dimethyl-fumarate-in-multiple-sclerosis-latest-developments-evidence-and-place-in-therapy
#14
REVIEW
Ralf A Linker, Aiden Haghikia
Dimethyl fumarate (DMF) is one of the newer additions to the armamentarium of potent immunomodulators for the treatment of relapsing-remitting multiple sclerosis (RRMS). After more than 2 years of real-world experience and more than 190,000 patients currently treated with DMF worldwide, it is a good timepoint to review the experience gathered so far and to re-evaluate the potential of this first-line oral multiple sclerosis (MS) drug. Post-hoc analyses of clinical and magnetic resonance imaging (MRI) data, some comprising more than 6 years of drug exposure including patients from the clinical trials, and the overall notion in clinical practice widely confirm the good efficacy of DMF in RRMS...
July 2016: Therapeutic Advances in Chronic Disease
https://www.readbyqxmd.com/read/27433309/h-p-acthar-gel-repository-corticotropin-injection-treatment-of-patients-with-multiple-sclerosis-and-diabetes
#15
Christen Kutz
BACKGROUND: Treatment of multiple sclerosis (MS) relapses can be complex in patients with concomitant diabetes. Corticosteroids and adrenocorticotropic hormones are known to cause alterations in glucose tolerance. Many patients have poor tolerability to therapy, necessitating alternative treatment options. Adrenocorticotropic hormone (H.P. Acthar Gel, repository corticotropin injection, Mallinckrodt ARD Inc., Hazelwood, MO, USA) is currently indicated for the treatment of MS relapses...
July 2016: Therapeutic Advances in Chronic Disease
https://www.readbyqxmd.com/read/27347365/corrigendum
#16
(no author information available yet)
[This corrects the article DOI: 10.1177/2040622315579059.].
May 2016: Therapeutic Advances in Chronic Disease
https://www.readbyqxmd.com/read/27347364/current-and-future-treatment-options-for-cystic-fibrosis-lung-disease-latest-evidence-and-clinical-implications
#17
REVIEW
Claire Edmondson, Jane C Davies
Treatment for cystic fibrosis (CF) has conventionally targeted downstream consequences of the defect such as mucus plugging and infection. More recently, significant advances have been made in treating the root cause of the disease, namely a defective CF transmembrane conductance regulator (CFTR) gene. This review summarizes current pulmonary treatment options and highlights advances in research and development of new therapies.
May 2016: Therapeutic Advances in Chronic Disease
https://www.readbyqxmd.com/read/27347363/patient-reported-functioning-in-major-depressive-disorder
#18
Waguih William IsHak, David M James, James Mirocha, Haidy Youssef, Gabriel Tobia, Sarah Pi, Katherine L Collison, Robert M Cohen
OBJECTIVES: Compared with the general population, patients with major depressive disorder (MDD) report substantial deficits in their functioning that often go beyond the clinical resolution of depressive symptoms. This study examines the impact of MDD and its treatment on functioning. METHODS: From the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial, we analyzed complete data of 2280 adult outpatients with MDD at entry and exit points of each level of antidepressant treatment and again 12 months post treatment...
May 2016: Therapeutic Advances in Chronic Disease
https://www.readbyqxmd.com/read/27347362/the-prevalence-and-clinical-characteristics-associated-with-diagnostic-and-statistical-manual-version-5-defined-anxious-distress-specifier-in-adults-with-major-depressive-disorder-results-from-the-international-mood-disorders-collaborative-project
#19
Roger S McIntyre, Hanna O Woldeyohannes, Joanna K Soczynska, Maj Vinberg, Danielle S Cha, Yena Lee, Laura A Gallaugher, Roman S Dale, Mohammad T Alsuwaidan, Rodrigo B Mansur, David J Muzina, Andre Carvalho, Sidney Kennedy
OBJECTIVES: The aim of the study was to evaluate the prevalence of and illness characteristics in adults with major depressive disorder (MDD) with anxious distress specifier (ADS) enrolled in the International Mood Disorders Collaborative Project, which is a collaborative research platform at the Mood Disorders Psychopharmacology Unit, University of Toronto, Canada and the Cleveland Clinic, Cleveland, Ohio, USA. METHODS: Data from participants who met criteria for a current major depressive episode as part of MDD (n = 830) were included in this post hoc analysis...
May 2016: Therapeutic Advances in Chronic Disease
https://www.readbyqxmd.com/read/27347361/pre-exposure-prophylaxis-as-hiv-prevention-in-the-uk
#20
Michael Brady
No abstract text is available yet for this article.
May 2016: Therapeutic Advances in Chronic Disease
journal
journal
43051
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"